1-6 of 6
Marika Sherman
Close
Sort by
Journal Articles

Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Sattva S. Neelapu, Julio C. Chavez, Alison R. Sehgal, Narendranath Epperla, Matthew L. Ulrickson, Emmanuel Bachy, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph D. Rosenblatt, Marika Sherman, Jinghui Dong, Alessandro Giovanetti, Yin Yang, Christine Lui, Zahid Bashir, A Scott Jung, Caron Jacobson
Journal: Blood
Blood (2021) 138 (Supplement 1): 93.
https://doi.org/10.1182/blood-2021-148473
Published: 2021
Journal Articles

ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma

Ran Reshef, MDMSc, David B. Miklos, MD PhD, John M. Timmerman, MD, Caron A. Jacobson, MD MMSc, Nabila N. Bennani, MD, John M. Rossi, MS, Marika Sherman, MS, Lianqing Zheng, PhD, Jennifer Sun, MS, Gabrielle Palluconi, BS, Jenny J. Kim, MD MS, Michael D. Jain, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4084.
https://doi.org/10.1182/blood-2019-123772
Published: 2019
Journal Articles

Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)

Frederick L. Locke, MD, Sattva S. Neelapu, MD, Nancy L. Bartlett, MD, Lazaros J. Lekakis, MD, Caron A. Jacobson, MD, Ira Braunschweig, MD, Olalekan O. Oluwole, MBBS, MPH, Tanya Siddiqi, MD, Yi Lin, MD PhD, John M Timmerman, MD, Patrick M. Reagan, MD, Adrian Bot, MD PhD, John M. Rossi, MS, Marika Sherman, MS, Lynn Navale, MS, Yizhou Jiang, PhD, Jeff S. Aycock, Meg Elias, RN,BSN, Jeffrey S. Wiezorek, MD MS, William Y. Go, MD PhD, David B. Miklos, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1547.
https://doi.org/10.1182/blood.V130.Suppl_1.1547.1547
Published: 2017
Journal Articles

Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy

Adrian Bot, MD PhD, John M. Rossi, MS, Yizhou Jiang, PhD, Lynn Navale, MS, Yueh-wei Shen, MS, Marika Sherman, MS, Armen Mardiros, PhD, Sean C. Yoder, MS, William Y. Go, MD PhD, Steven A. Rosenberg, MD PhD, Jeff Wiezorek, MD MS, David D. Chang, MD PhD, James N. Kochenderfer, MD, Margo R. Roberts, PhD
Journal: Blood
Blood (2015) 126 (23): 4426.
https://doi.org/10.1182/blood.V126.23.4426.4426
Published: 2015
Journal Articles

Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

John M. Rossi, MS, Sattva S. Neelapu, MD, William Y. Go, MD PhD, Yueh-wei Shen, MS, Marika Sherman, MS, Frederick L. Locke, MD, Nancy L Bartlett, MD, Tanya Siddiqi, MD, Lynn Navale, MS, Meg Elias, RN,BSN, Jeff Wiezorek, MD MS, Adrian Bot, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2730.
https://doi.org/10.1182/blood.V126.23.2730.2730
Published: 2015
Journal Articles

Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy

Arianne Perez, PhD, Lynn Navale, MS, John M. Rossi, MS, Yueh-wei Shen, MS, Yizhou Jiang, PhD, Marika Sherman, MS, Armen Mardiros, PhD, Sean C. Yoder, MS, William Y. Go, MD PhD, Steven A. Rosenberg, MD PhD, Jeff Wiezorek, MD MS, Margo R. Roberts, PhD, David D. Chang, MD PhD, James N. Kochenderfer, MD, Adrian Bot, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2042.
https://doi.org/10.1182/blood.V126.23.2042.2042
Published: 2015